ITCI pipeline is focused on three platforms: The ITI-007 platform, of which lumateperone is the most advanced program; the PDE platform, of which ITI-214, a PDE1 inhibitor, is the most advanced program; and our discovery platform, which includes ITI-333.
Corporate Headquarters:
430 East 29th Street
Suite 900
New York, NY 10016
Tel +1 (646) 440-9333
Fax +1 (646) 440-9334
Corporate Headquarters:
430 East 29th Street
Suite 900
New York, NY 10016
Tel +1 (646) 440-9333
Fax +1 (646) 440-9334